Clinical Advisory Panel
GlyTherix draws upon the expertise of six internationally esteemed medical experts on its Clinical Advisory Panel
Dr Alan Harris (Chair)
Dr. Harris is a senior physician-scientist (MD, PhD) and pharmaceutical drug development executive, he has over 30 years of experience in the biotechnology/pharmaceutical industries and academia. He has served as an associate professor at UCLA Cedars Sinai Medical Center and an adjunct professor at NYU Grossman School of Medicine since 2003. His expertise spans the clinical development and approval of 17 drugs, including therapeutic peptide analogs, and he has managed various aspects of drug development in both small biotech and large pharmaceutical companies.
He spearheaded the development of the somatostatin peptide analog octreotide (Sandostatin®), approved in 1988, which remains a key treatment for malignant neuroendocrine tumors and acromegaly. He also contributed to the development of the first peptide-based diagnostic imaging agent, Octreoscan, and advised on the development of somatostatin-based receptor-targeted therapeutics, including LUTATHERA®. He has chaired the inaugural NIH/NCI-sponsored 2022 Gordon Research Conference on Radioonuclide Theranostics in Cancer and founded several companies, including Sompharmaceuticals and Grafton Therapeutics.
In addition to his entrepreneurial ventures, he has been an advisor to Partners Healthcare System Innovation and has supported Harvard Medical School faculty. He holds eight patents and has significantly contributed to the fields of endocrinology, oncology, and radiopharmaceuticals.

Professor David Gillatt
Professor Gillatt is the Director of Medical and Surgical Services and Professor of Urological Oncology and Robotic Surgery at Macquarie University Hospital. In these roles, he focuses on enhancing the hospital’s multidisciplinary approach to prostate cancer care, ensuring coordinated services across various specialties. His work includes both clinical practice and research, particularly in the areas of prostate and bladder cancer. Professor Gillatt has published extensively, with nearly 300 peer-reviewed articles.

Dr Neal Shore
Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network,the APCCC Scientific Steering Committee,Maple Tree Cancer Alliance,Alessa Therapeutics, Photocure, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and the co-chair of the annual AUA International Prostate Forum. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice,JUOP and World Journal of Urology. He is the Editor of Reviews in Urology and serves as an Editor of Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.

Dr John Babich
Professor Babich is a distinguished expert in radiopharmaceutical sciences, currently serving as the Founder, President, and Chief Scientific Officer of Ratio Therapeutics. Before founding Ratio Therapeutics, he was the Chief of Radiopharmaceutical Sciences in Radiology at Weill Cornell Medical College.
Professor Babich has dedicated much of his career to developing novel molecular imaging tools for medical diagnostics and therapeutics. He co-founded Molecular Insight Pharmaceuticals, which was later acquired by Progenics Pharmaceuticals, and has been instrumental in creating radiolabeled small molecules for visualizing and treating prostate cancer. His work has significantly advanced the field of targeted radiotherapy, earning him international recognition.
In addition to his entrepreneurial ventures, Professor Babich has collaborated extensively with colleagues in urology, oncology, and surgery to improve cancer detection and patient management. His innovative protocols combining radiopharmaceuticals and PET scans have enhanced early cancer detection, particularly in prostate cancer. His contributions to the field are reflected in his numerous publications and patents, solidifying his reputation as a leader in radiopharmaceutical sciences.

Dr Elcin Zan
Dr Zan is Chair of Nuclear Medicine at Cleveland Clinic. Elcin focuses on exploring the full potential of Radiopharmaceutical Therapies in oncology to meaningfully improve patient outcomes in clinic and research. Elcin and her team develop AGI tools to study the collective intelligence of cancer from cells to body-wide networks integrating pathology and PET diagnostics.
Prior to joining Cleveland Clinic, Dr Zan was a Nuclear Medicine Physician and Neuroradiologist at Weill Cornell Medicine, NY and served as the director of PET/MRI, providing radiopharmaceutical therapies for neuroendocrine tumors and prostate cancer.
Dr Zan has also been the Director of Nuclear Theranostics and Neuroendocrine Disease Management Team at NYU Langone Health. She served as the Co-PI in radiopharmaceutical clinical trials in meningiomas and pancreas adenocarcinomas.
Dr Zan is an active member of national and international societies including SNMMI, EANM, RSNA, ASCO, ESMO, SITC, and ICPO reflecting her diverse background and interests in utilizing radiopharmaceutical therapies to improve patient outcomes.

Dr Colin Hayward
Dr. Hayward brings significant experience in the pharmaceutical and biotechnology industries, particularly in the development of radiopharmaceuticals for the treatment of cancer and other serious diseases. Additionally, he has expertise in the areas of clinical development, medical affairs, and regulatory affairs. His role have involved the advancement of innovative treatments in oncology, especially those involving targeted therapies, imaging agents, and radiopharmaceuticals, including the development of Illuccix whilst Chief Medical Officer at Telix Pharmaceuticals.